Effects of Pravastatin on Human Placenta, Endothelium, and Women with Severe Preeclampsia

Hypertension

Volumn 66, Issue 3, 2015, Pages 687-697

  Brownfoot, Fiona C ^a   Tong, Stephen ^a   Hannan, Natalie J ^a   Binder, Natalie K ^a   Walker, Susan P ^a   Cannon, Ping ^a   Hastie, Roxanne ^a   Onda, Kenji ^a,b   Kaitu'U Lino, Tu'Uhevaha J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

antioxidants; placenta; pravastatin; preeclampsia; pregnancy; trophoblasts

Indexed keywords

ENDOGLIN; FARNESYL DIPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; PRAVASTATIN; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN RECEPTOR 1; CADM1 PROTEIN, HUMAN; CELL ADHESION MOLECULE; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; FLT1 PROTEIN, HUMAN; IMMUNOGLOBULIN; LEUKOCYTE ANTIGEN;

ADULT; ARTICLE; CASE REPORT; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DISEASE SEVERITY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LEUKOCYTE ADHERENCE; MONOCYTE; OXIDATIVE STRESS; PLACENTA; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TROPHOBLAST; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; DRUG EFFECTS; ENDOTHELIUM CELL; METABOLISM; PRE-ECLAMPSIA; PREGNANCY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM; YOUNG ADULT;

ADULT; ANTIGENS, CD; CELL ADHESION MOLECULES; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOGLOBULINS; PLACENTA; PRAVASTATIN; PRE-ECLAMPSIA; PREGNANCY; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TROPHOBLASTS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; YOUNG ADULT;

EID: 84939241752     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.05445     Document Type: Article

References (37)

1. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308:1592-1594. doi: 10.1126/science.1111726.
2. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365:785-799. doi: 10.1016/S0140-6736(05)17987-2.
3. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649-658. doi: 10.1172/JCI17189.
4. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12:642-649. doi: 10.1038/nm1429.
5. Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation. 2011;123:2856-2869. doi: 10.1161/CIRCULATIONAHA.109.853127.
6. Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Annu Rev Pathol. 2010;5:173-192. doi: 10.1146/ annurev-pathol-121808-102149.
7. Chaiworapongsa T, Chaemsaithong P, Yeo L, Romero R. Pre-eclampsia part 1: current understanding of its pathophysiology. Nat Rev Nephrol. 2014;10:466-480. doi: 10.1038/nrneph.2014.102.
8. LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the lipid trial follow-up. Lancet. 2002;359:1379-1387.
9. Shaw SM, Fildes JE, Yonan N, Williams SG. Pleiotropic effects and cholesterol-lowering therapy. Cardiology. 2009;112:4-12. doi: 10.1159/000137692.
10. Cudmore M, Ahmad S, Al-Ani B, Fujisawa T, Coxall H, Chudasama K, Devey LR, Wigmore SJ, Abbas A, Hewett PW, Ahmed A. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation. 2007;115:1789-1797. doi: 10.1161/CIRCULATIONAHA. 106.660134.
11. Lecarpentier E, Morel O, Fournier T, Elefant E, Chavatte-Palmer P, Tsatsaris V. Statins and pregnancy: between supposed risks and theoretical benefits. Drugs. 2012;72:773-788. doi: 10.2165/11632010-000000000-00000.
12. Godfrey LM, Erramouspe J, Cleveland KW. Teratogenic risk of statins in pregnancy. Ann Pharmacother. 2012;46:1419-1424. doi: 10.1345/ aph.1R202.
13. Nanovskaya TN, Patrikeeva SL, Paul J, Costantine MM, Hankins GD, Ahmed MS. Transplacental transfer and distribution of pravastatin. Am J Obstet Gynecol. 2013;209:373.e1-e5. doi: 10.1016/ j.ajog.2013.05.038.
14. The stamp trial: a proof of principle, double-blind, randomised placebocontrolled, multicentre trial of pravastatin to ameliorate early onset preeclampsia. 2012.
15. Costantine MM, Cleary K; Eunice Kennedy Shriver National Institute of Child Health and Human Development Obstetric-Fetal Pharmacology Research Units Network. Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obstet Gynecol. 2013;121(2 pt 1):349-353. doi: http://10.1097/AOG.0b013e31827d8ad5.
16. Costantine MM, Tamayo E, Lu F, Bytautiene E, Longo M, Hankins GD, Saade GR. Using pravastatin to improve the vascular reactivity in a mouse model of soluble fms-like tyrosine kinase-1-induced preeclampsia. Obstet Gynecol. 2010;116:114-120. doi: 10.1097/AOG.0b013e3181e10ebd.
17. Fox KA, Longo M, Tamayo E, Kechichian T, Bytautiene E, Hankins GD, Saade GR, Costantine MM. Effects of pravastatin on mediators of vascular function in a mouse model of soluble Fms-like tyrosine kinase-1-induced preeclampsia. Am J Obstet Gynecol. 2011;205:366.e1-366.e5. doi: 10.1016/j.ajog.2011.06.083.
18. Kumasawa K, Ikawa M, Kidoya H, Hasuwa H, Saito-Fujita T, Morioka Y, Takakura N, Kimura T, Okabe M. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci U S A. 2011;108:1451-1455. doi: 10.1073/pnas.1011293108.
19. Bauer AJ, Banek CT, Needham K, Gillham H, Capoccia S, Regal JF, Gilbert JS. Pravastatin attenuates hypertension, oxidative stress, and angiogenic imbalance in rat model of placental ischemia-induced hypertension. Hypertension. 2013;61:1103-1110. doi: 10.1161/HYPERTENSIONAHA. 111.00226.
20. Kodama Y, Kitta Y, Nakamura T, Takano H, Umetani K, Fujioka D, Saito Y, Kawabata K, Obata JE, Mende A, Kobayashi T, Kugiyama K. Atorvastatin increases plasma soluble Fms-like tyrosine kinase-1 and decreases vascular endothelial growth factor and placental growth factor in association with improvement of ventricular function in acute myocardial infarction. J Am Coll Cardiol. 2006;48:43-50. doi: 10.1016/j.jacc.2006.03.035.
21. American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the american college of obstetricians and gynecologists' task force on hypertension in pregnancy. Obstet Gynecol. 2013;122:1122-1131. doi: 10.1097/01.AOG.0000437382.03963.88.
22. Brownfoot FC, Hannan N, Onda K, Tong S, Kaitu'u-Lino T. Soluble endoglin production is upregulated by oxysterols but not quenched by pravastatin in primary placental and endothelial cells. Placenta. 2014;35:724-731. doi: 10.1016/j.placenta.2014.06.374.
23. Tu'uhevaha J, Kaitu'u-Lino ST, Sally B, Roxanne H, Laura T, Fiona B, Kenji O, Natalie JH. Characterization of protocols for primary trophoblast purification, optimized for functional investigation of sflt-1 and soluble endoglin. Pregnancy Hypertension. 2014;4:287-295.
24. Onda K, Tong S, Nakahara A, Kondo M, Monchusho H, Hirano T, Kaitu'u-Lino T, Beard S, Binder N, Tuohey L, Brownfoot F, Hannan NJ. Sofalcone upregulates the nuclear factor (erythroid-derived 2)-like 2/heme oxygenase-1 pathway, reduces soluble fms-like tyrosine kinase-1, and quenches endothelial dysfunction: potential therapeutic for preeclampsia. Hypertension. 2015;65:855-862. doi: 10.1161/HYPERTENSIONAHA.114.04781.
25. Whitehead CL, Palmer KR, Nilsson U, Gao Y, Saglam B, Lappas M, Tong S. Placental expression of a novel primate-specific splice variant of sFlt-1 is upregulated in pregnancies complicated by severe early onset pre-eclampsia. BJOG. 2011;118:1268-1271. doi: 10.1111/j.1471-0528.2011.02962.x.
26. Jebbink J, Keijser R, Veenboer G, van der Post J, Ris-Stalpers C, Afink G. Expression of placental FLT1 transcript variants relates to both gestational hypertensive disease and fetal growth. Hypertension. 2011;58:70-76. doi: 10.1161/HYPERTENSIONAHA.110.164079.
27. Borzychowski AM, Sargent IL, Redman CW. Inflammation and preeclampsia. Semin Fetal Neonatal Med. 2006;11:309-316. doi: 10.1016/j. siny.2006.04.001.
28. Sánchez-Aranguren LC, Prada CE, Riaño-Medina CE, Lopez M. Endothelial dysfunction and preeclampsia: role of oxidative stress. Front Physiol. 2014;5:372. doi: 10.3389/fphys.2014.00372.
29. Nishikawa S, Miyamoto A, Yamamoto H, Ohshika H, Kudo R. The relationship between serum nitrate and endothelin-1 concentrations in preeclampsia. Life Sci. 2000;67:1447-1454.
30. Thadhani R, Kisner T, Hagmann H, et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation. 2011;124:940-950. doi: 10.1161/CIRCULATIONAHA.111.034793.
31. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355:992-1005. doi: 10.1056/ NEJMoa055352.
32. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672-683. doi: 10.1056/ NEJMoa031884.
33. Gangooly S, Muttukrishna S, Jauniaux E. In-vitro study of the effect of anti-hypertensive drugs on placental hormones and angiogenic proteins synthesis in pre-eclampsia. PLoS One. 2014;9:e107644. doi: 10.1371/ journal.pone.0107644.
34. Nachtigal P, Pospisilova N, Vecerova L, Micuda S, Brcakova E, Pospechova K, Semecky V. Atorvastatin increases endoglin, SMAD2, phosphorylated SMAD2/3 and eNOS expression in ApoE/LDLR double knockout mice. J Atheroscler Thromb. 2009;16:265-274.
35. Xu B, Thornton C, Tooher J, Ogle R, Lim S, Makris A, Hennessy A. Effects of anti-hypertensive drugs on production of soluble fms-like tyrosine kinase 1 and soluble endoglin from human normal and pre-eclamptic placentas in vitro. Clin Exp Pharmacol Physiol. 2009;36:839-842. doi: 10.1111/j.1440-1681.2009.05155.x.
36. Nayeri UA, Buhimschi IA, Laky CA, Cross SN, Duzyj CM, Ramma W, Sibai BM, Funai EF, Ahmed A, Buhimschi CS. Antenatal corticosteroids impact the inflammatory rather than the antiangiogenic profile of women with preeclampsia. Hypertension. 2014;63:1285-1292. doi: 10.1161/ HYPERTENSIONAHA.114.03173.
37. Lefkou E, Mamopoulos A, Fragakis N, Dagklis T, Vosnakis C, Nounopoulos E, Rousso D, Girardi G. Clinical improvement and successful pregnancy in a preeclamptic patient with antiphospholipid syndrome treated with pravastatin. Hypertension. 2014;63:e118-e119. doi: 10.1161/ HYPERTENSIONAHA.114.03115.